云南白药(000538) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥10,327,715,582.47, a decrease of 8.70% compared to the same period last year[4] - Net profit attributable to shareholders was ¥763,157,801.48, an increase of 19.81% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥1,365,307,573.86, down 3.34% from the previous year[4] - Basic earnings per share were ¥0.6, reflecting an increase of 18.33% year-on-year[4] - The company's net profit for 2021 was CNY 279,634,000, a decrease of CNY 271,470,000 or -49.26% compared to 2020's net profit of CNY 551,104,000[21] - Net profit attributable to shareholders of the parent company was ¥914,368,241.49, compared to ¥763,157,801.48 in the same period last year, representing a growth of 19.7%[29] Cash Flow - The net cash flow from operating activities was -¥128,050,971.43, a decline of 33.00% compared to the previous year[4] - Cash flow from operating activities was ¥8,868,217,236.81, an increase from ¥8,565,705,655.77 in the previous year, indicating a growth of 3.5%[30] - The net cash flow from operating activities was -170,306,941.45 CNY, compared to -128,050,971.43 CNY in the previous year, indicating a decline in operational cash flow[31] - The total cash and cash equivalents at the end of the period were 10,669,753,998.57 CNY, down from 13,724,291,694.91 CNY year-over-year[32] - Cash outflow for operating activities totaled 9,187,760,379.36 CNY, compared to 8,777,686,067.49 CNY in the previous year, indicating increased operational expenses[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥52,292,765,646.22, up 1.58% from the end of the previous year[4] - The total current assets at the end of the reporting period amounted to CNY 35,434,922,089.45, down from CNY 45,503,949,943.31 at the beginning of the year[25] - The total liabilities decreased to ¥13,639,330,765.48 from ¥13,858,947,800.63, a reduction of 1.6%[28] - The company's total assets reached CNY 53,119,993,187.71, compared to CNY 52,292,765,646.22 at the beginning of the year[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 154,539[10] - Yunnan State-owned Equity Operation Management Co., Ltd. holds 25.03% of shares, totaling 321,160,222 shares, with 136,245,600 shares pledged[10] - Xinhua Dou Industrial Group Co., Ltd. holds 24.26% of shares, totaling 311,244,460 shares, with 207,510,000 shares pledged[10] - Public shareholders hold 1,382,215,800 shares of Wanlong Holdings, representing 21.44% of all issued shares[14] Investments and Acquisitions - The company reported a significant increase in goodwill by 1114.74% due to business combinations[9] - The cash flow from investing activities showed a net outflow of -¥8,166,681,896.54, a decrease of 1452.69% compared to the previous year[9] - The company has successfully acquired 1,319,881,798 shares of Wanlong Holdings, representing 20.47% of all issued shares, as part of a comprehensive offer[12] - The total shares held by the company and its concerted parties reached 5,065,936,360 shares, accounting for 78.56% of Wanlong Holdings[14] Research and Development - The company appointed Mr. Zhang Ning as the Chief Scientist to enhance its R&D capabilities in traditional Chinese medicine and advanced biopharmaceuticals[15] - The company is actively expanding its R&D pipeline while integrating various product forms to create comprehensive pharmaceutical solutions[15] - Research and development expenses were ¥52,322,884.63, slightly down from ¥53,003,570.53 in the previous year[28] Future Outlook - Yunnan Baiyao plans to distribute a cash dividend of 16 yuan per 10 shares and issue 4 bonus shares per 10 shares, with the total distribution amount to be adjusted based on the number of shares at the time of the dividend distribution[19] - The company aims for a net profit in 2022 that is not less than the same period last year, focusing on its "New Baiyao, Big Health" strategy[20] - The estimated total amount of daily related transactions with Jiangsu Yuyue Medical Equipment Co., Ltd. and Kunming Hongyun Hospital Co., Ltd. for 2022 is 34.1 million yuan[20] Board and Governance - Yunnan Baiyao's board approved the 2021 annual reports and proposed a budget for 2022 during the board meeting on March 24, 2022[19] - The board has authorized the group office to approve external investments and donations within specified limits, enhancing operational flexibility[21] - The company will hold an online performance briefing on April 8, 2022, to discuss its 2021 annual operating results[23]